TFF Pharmaceuticals Q1 2024 GAAP EPS $(2.40) Misses $(2.26) Estimate, Sales $203.27K Beat $75.00K Estimate
TFF Pharmaceuticals Q1 2024 GAAP EPS $(2.40) Misses $(2.26) Estimate, Sales $203.27K Beat $75.00K Estimate
TFF Pharmicals 2024年第一季度GAAP每股收益（2.40）未達到預期（2.26）美元，銷售額20.327萬美元超過7.5萬美元的預期
TFF Pharmaceuticals (NASDAQ:TFFP) reported quarterly losses of $(2.40) per share which missed the analyst consensus estimate of $(2.26) by 6.19 percent. The company reported quarterly sales of $203.27 thousand which beat the analyst consensus estimate of $75.00 thousand by 171.03 percent. This is a 295.25 percent increase over sales of $51.43 thousand the same period last year.
TFF Pharmicals（納斯達克股票代碼：TFFP）公佈的季度虧損爲每股2.40美元，比分析師普遍預期的2.26美元（2.26美元）低6.19％。該公司公佈的季度銷售額爲203,270美元，比分析師普遍預期的7.5萬美元高出171.03％。這比去年同期的51,430美元的銷售額增長了295.25％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。